Learn about our comprehensive antibody validation methods to ensure monospecificity.  Antibody Validation>>

Recombinant HLA-DR (MHC II) Antibody [HLA-DRA/6840R]

In Stock
Catalog Number Formulation Size Price
3122-RBM6-P0
Purified Ab with BSA and Azide at 200ug/ml
20ug
$229.00
3122-RBM6-P1
Purified Ab with BSA and Azide at 200ug/ml
100ug
$519.00
3122-RBM6-P1ABX
Purified Ab WITHOUT BSA and Azide at 1.0mg/ml
100ug
$519.00
Flat Rate Domestic: $60 | Orders outside the US - Contact Us for Order Information | Ships next business day

Applications & Dilutions

Applications Tested Dillution Protocol Note
Immunohistochemistry (IHC)
1-2ug/ml
30 min at RT. Staining of formalin-fixed tissues requires heating tissue sections in 10mM Tris with 1mM EDTA, pH 9.0, for 45 min at 95°C followed by cooling at RT for 20 minutes

Summary

This MAb reacts with the beta-chain of HLA-DR antigen, a member of MHC class II molecules. Â �It does not cross react with HLA-DP and HLA-DQ. The L243 antibody recognizes a different epitope than the HLA-DRA/6840R monoclonal antibody, and these antibodies do not cross-block binding to each other's respective epitopes. HLA-DR is a heterodimeric cell surface glycoprotein comprised of a 36kDa alpha (heavy) chain and a 28kDa beta (light) chain. It is expressed on B-cells, activated T-cells, monocytes/macrophages, dendritic cells and other non-professional APCs. In conjunction with the CD3/TCR complex and CD4 molecules, HLA-DR is critical for efficient peptide presentation to CD4+ T cells. It is an excellent histiocytic marker in paraffin sections producing intense staining. True histiocytic neoplasms are similarly positive. HLA-DR antigens also occur on a variety of epithelial cells and their corresponding neoplastic counterparts.

Product Properties & Targets

Host
Rabbit
Applications
Species Reactivity
Isotype / Light Chain
IgG / Kappa
Cellular Localization
Cell surface.
Gene Name
Positive Control
Human tonsil or lymph node.
Immunogen
Recombinant fragment (around aa1-200) of human HLA-DR protein (exact sequence is proprietary)
Alternate Names
HLA class II histocompatibility antigen, DR alpha chain, MHC class II antigen DRA, DRB1; DRB4; HLA class II histocompatibility antigen DR alpha chain; HLA DR1B; HLA DR3B; HLA DRA; HLA DRA1; HLA DRB1; HLA DRB3; HLA DRB4; HLA DRB5; HLA-DRA; HLADR4B; HLADRA1; HLADRB; Major histocompatibility complex class II DR beta 1 / 3/ 4; Major histocompatibility complex class II DR beta 5; MHC cell surface glycoprotein

Database Links

Entrez Gene ID
SwissProt

Additional Information

Clone
HLA-DRA/6840R
Chromosome Location
6p21.3
Mol. Weight of Antigen
~28kDa (beta chain)

Functions

  • An alpha chain of antigen-presenting major histocompatibility complex class II (MHCII) molecule. In complex with the beta chain HLA-DRB, displays antigenic peptides on professional antigen presenting cells (APCs) for recognition by alpha-beta T cell receptor (TCR) on HLA-DR-restricted CD4-positive T cells. This guides antigen-specific T-helper effector functions, both antibody-mediated immune response and macrophage activation, to ultimately eliminate the infectious agents and transformed cells (PubMed:29884618, PubMed:17334368, PubMed:8145819, PubMed:15322540, PubMed:22327072, PubMed:27591323, PubMed:31495665, PubMed:15265931, PubMed:9075930, PubMed:24190431). Typically presents extracellular peptide antigens of 10 to 30 amino acids that arise from proteolysis of endocytosed antigens in lysosomes (PubMed:8145819). In the tumor microenvironment, presents antigenic peptides that are primarily generated in tumor-resident APCs likely via phagocytosis of apoptotic tumor cells or macropinocytosis of secreted tumor proteins (PubMed:31495665). Presents peptides derived from intracellular proteins that are trapped in autolysosomes after macroautophagy, a mechanism especially relevant for T cell selection in the thymus and central immune tolerance (PubMed:17182262, PubMed:23783831). The selection of the immunodominant epitopes follows two processing modes: 'bind first, cut/trim later' for pathogen-derived antigenic peptides and 'cut first, bind later' for autoantigens/self-peptides (PubMed:25413013). The anchor residue at position 1 of the peptide N-terminus, usually a large hydrophobic residue, is essential for high affinity interaction with MHCII molecules (PubMed:8145819).

Key References

  • Johnson MD, et al. Archives of Pathology and Laboratory Medicine, 1988, 112(2):155-60.

PubMed Links

Storage & Stability

Antibody with azide - store at 2 to 8°C. Antibody without azide - store at -20 to -80°C. Antibody is stable for 24 months. Non-hazardous. No MSDS required.

Limitations

This antibody is available for research use only and is not approved for use in diagnosis.

Supplied as

200ug/ml of Ab purified from Bioreactor Concentrate by Protein A/G. Prepared in 10mM PBS with 0.05% BSA & 0.05% azide. Also available WITHOUT BSA & azide at 1.0mg/ml.

Warranty

There are no warranties, expressed or implied, which extend beyond this description. Company is not liable for any personal injury or economic loss resulting from this product.

Reviews

There are no reviews yet.

Be the first to review “Recombinant HLA-DR (MHC II) Antibody”

Your email address will not be published. Required fields are marked *

PARTNERSHIP OPPORTUNITIES

We hold Exclusive rights to 10,000 recombinant and hybridoma antibody products, available for Licensing or Collaboration.

LETS TALK